Syncona’s Beacon investment reports positive pivotal vision-study results
Syncona ($SYNC)’s portfolio company Beacon Therapeutics reported positive topline results from its Phase II/III VISTA trial of laru-zova for X-linked retinitis pigmentosa. At 12 months, 31% of patients in the high-dose group and 24.1% in the low-dose group achieved an improvement of at least 15 letters on a low-light eye-chart assessment, compared with no responders in the untreated control group. Both comparisons were statistically significant, meeting the study’s primary endpoint. Beacon descr
0